Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19

NEJM – Cases of recurrence of clinical symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after completion of treatment with nirmatrelvir–ritonavir have been reported by researchers¹ and in a Centers for Disease Control and Prevention Health Advisory.² The frequency and clinical implications of potential recurrence of coronavirus disease 2019 (Covid-19) are unknown.